Immunexpress develops molecular diagnostic assays that quantify, directly from whole blood, specific molecular markers of the patient’s immune "host response." Its lead assay is SeptiCyte RAPID, which the company intends to pursue regulatory clearance for. The company said it closed a major private funding round to advance its near-term objectives. Proceeds are intended to support 510(k) clearance of SeptiCyte RAPID from the U.S. Food and Drug Administration and the commercial launch of the assay. Leadership is headed by CEO Rolland D. Carlson, Ph.D. The company is based in Seattle, WA. Financial details of the round, including amount and investors, were not disclosed in the article. Immunexpress Group is based in Brisbane, Australia and Seattle, USA, and is led by President and CEO Dr Roslyn Brandon. The company focuses on improving outcomes for patients with, or at risk of, sepsis by specializing in clinical validation of genomic and proteomic biomarkers. It translates novel biomarkers into clinical diagnostic and monitoring assays for readily available platforms, including point-of-care (POC). Its SeptiCyte® technology quantifies multiple specific molecular markers from the patient’s immune system for earlier diagnosis, detection, triage, screening, severity assessment, and for better timing and targeting of therapies. The company intends to use recent funding to advance development of the SeptiCyte® technology and bring one of its late-stage sepsis diagnostic products to market. No operating metrics (revenue/users) were reported in the articles.

Total raised

$6M

Funding rounds

2

Latest round

Equity

Latest activity

Mar 2014